Lantanon

Mianserin hydrochloride, the active ingredient in Lantanon, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients and works by modulating neurotransmitter activity to improve mood and alleviate depressive symptoms.

GNH USA supplies Lantanon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable global distribution. The company adheres to stringent regulatory standards and provides comprehensive support for product registration and logistics.

Lantanon (mianserin hydrochloride) is used within the antidepressant drug class to treat depressive disorders.

Major depressive disorder (single episode): reduces depressive symptoms and improves mood. Major depressive disorder (recurrent): helps prevent relapse and sustain remission. Depressive symptoms with associated insomnia: may improve sleep quality alongside mood.

Common Side Effects: - Dry mouth - Sedation or drowsiness - Weight gain - Constipation - Dizziness - Increased appetite

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Cardiac arrhythmias (e.g., QT prolongation) - Severe hypotension - Suicidal thoughts or behavior - Hepatotoxicity

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood pressure: watch for orthostatic hypotension, especially at treatment start. - Assess for suicidal ideation: increased risk may occur in early treatment phases. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Review concomitant CNS depressants: risk of enhanced sedation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mianserin hydrochloride can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: potential serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, barbiturates): additive sedation.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may potentiate hypotensive effects. - Anticholinergic drugs: increased anticholinergic burden. - Alcohol: enhances sedative properties and dizziness. - CYP2D6 inhibitors: may raise mianserin plasma levels.